Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10475
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Davis, Ian D | en |
dc.contributor.author | Skak, Kresten | en |
dc.contributor.author | Smyth, Mark J | en |
dc.contributor.author | Kristjansen, Paul E G | en |
dc.contributor.author | Miller, Dennis M | en |
dc.contributor.author | Sivakumar, Pallavur V | en |
dc.date.accessioned | 2015-05-15T23:56:01Z | |
dc.date.available | 2015-05-15T23:56:01Z | |
dc.date.issued | 2007-12-01 | en |
dc.identifier.citation | Clinical Cancer Research; 13(23): 6926-32 | en |
dc.identifier.govdoc | 18056166 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10475 | en |
dc.description.abstract | Interleukin-21 (IL-21) is a cytokine with structural and sequence homology to IL-2 and IL-15, yet possesses several biological properties distinct from these cytokines. IL-21 is produced mainly by activated CD4(+) T cells and natural killer T cells and mediates its activity by binding to the IL-21 receptor (IL-21R), consisting of an IL-21-specific alpha chain (IL-21Ralpha; JAK/STAT) that heterodimerizes with the common gamma chain (CD132). Intracellular signaling occurs through the Janus-activated kinase/signal transducer and activator of transcription pathways. Physiologic expression of IL-21R is restricted to lymphoid tissues and peripheral blood mononuclear cells; however, other tissues such as epithelium, synovium, or transformed cells can acquire expression of both components of IL-21R heterodimer. IL-21 has complex activities on a wide variety of cell types, leading to enhancement of adaptive T-cell immunity, antibody production, activation of natural killer cell subtypes, and opposition to suppressive effects mediated by regulatory T cells. Functionally, these activities promote immune responses and point to a physiologic role of IL-21 in autoimmunity and immune enhancement. Therapeutic manipulation of IL-21 activity may allow improved immunotherapy for cancer as well as insights into autoimmune disease. Recently conducted phase 1 trials in metastatic melanoma and renal cell carcinoma have shown that recombinant IL-21 has a favorable safety profile and support its continued investigation as a potential anticancer drug. | en |
dc.language.iso | en | en |
dc.subject.other | Animals | en |
dc.subject.other | Autoimmunity.physiology | en |
dc.subject.other | Humans | en |
dc.subject.other | Interleukins.immunology.metabolism.therapeutic use | en |
dc.subject.other | Neoplasms.immunology.metabolism.therapy | en |
dc.subject.other | Receptors, Interleukin-21.immunology.metabolism | en |
dc.subject.other | Signal Transduction | en |
dc.title | Interleukin-21 signaling: functions in cancer and autoimmunity. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical Cancer Research | en |
dc.identifier.affiliation | Ludwig-Austin Joint Medical Oncology Unit, Austin Health, Melbourne, Australia | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-07-1238 | en |
dc.description.pages | 6926-32 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/18056166 | en |
dc.type.austin | Journal Article | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.